Mepolizumab

Summary

Mepolizumab (CHEMBL2108429) is an approved antibody (ATC R03DX09); indicated across 12 conditions including obstructive lung disease and hypereosinophilic syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: R03DX09
• Indications: 12 conditions
• Clinical trials: 91

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108429
Name	Mepolizumab
Type	Antibody
Max phase	4
ATC	R03DX09

Also known as: Bosatria, Mepolizumab, Nucala, SB-240563, MEPOLIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obstructive lung disease	4	MONDO:0002267	HP:0006536
hypereosinophilic syndrome	4	MONDO:0015691	EFO:1001467
vasculitis	4	MONDO:0018882	EFO:0006803
chronic rhinosinusitis	4	MONDO:0006031	EFO:1000024
asthma	4	MONDO:0004979	MONDO:0004979
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
eosinophilic granulomatosis with polyangiitis	3	MONDO:0015943	EFO:0007208
nasal cavity polyp	3	MONDO:0006314	EFO:1000391
granulomatosis with polyangiitis	3	MONDO:0012105	EFO:0005297
eosinophilic esophagitis	2	MONDO:0005361	EFO:0004232

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 91.

Phase distribution

Phase	Trials
PHASE3	30
Not specified	26
PHASE2	14
PHASE4	12
PHASE1	3
PHASE2/PHASE3	2
PHASE1/PHASE2	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05598814	PHASE4	ACTIVE_NOT_RECRUITING	Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks
NCT05942222	PHASE4	ACTIVE_NOT_RECRUITING	A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT06041386	PHASE4	ACTIVE_NOT_RECRUITING	REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT07200336	PHASE4	NOT_YET_RECRUITING	Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
NCT07343661	PHASE4	ENROLLING_BY_INVITATION	Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
NCT04276233	PHASE4	COMPLETED	Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
NCT04585997	PHASE4	UNKNOWN	Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - Choosebetweenamab.
NCT04765722	PHASE4	COMPLETED	Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases
NCT04823585	PHASE4	COMPLETED	Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
NCT05642806	PHASE4	UNKNOWN	Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment
NCT05923047	PHASE4	UNKNOWN	Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.
NCT06107101	PHASE4	UNKNOWN	th2 Modulation CRSwNP
NCT04157348	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT05030155	PHASE3	ACTIVE_NOT_RECRUITING	Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
NCT05263934	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05979051	PHASE2/PHASE3	RECRUITING	A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
NCT00086658	PHASE3	COMPLETED	Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
NCT00097370	PHASE3	TERMINATED	Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
NCT01463644	PHASE3	COMPLETED	Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
NCT01520051	PHASE3	UNKNOWN	Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations
NCT01691508	PHASE3	COMPLETED	Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
NCT01691859	PHASE3	COMPLETED	MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
NCT01842607	PHASE3	COMPLETED	A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
NCT02020889	PHASE3	COMPLETED	A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
NCT02105948	PHASE3	COMPLETED	Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT02105961	PHASE3	COMPLETED	Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
NCT02135692	PHASE3	COMPLETED	A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
NCT02281318	PHASE3	COMPLETED	Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
NCT02555371	PHASE3	COMPLETED	Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
NCT02594332	PHASE3	TERMINATED	Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
NCT02836496	PHASE3	COMPLETED	Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
NCT03014674	PHASE3	COMPLETED	A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
NCT03021304	PHASE3	COMPLETED	Study of Mepolizumab Safety Syringe in Asthmatics
NCT03085797	PHASE3	COMPLETED	Effect of Mepolizumab in Severe Bilateral Nasal Polyps
NCT03099096	PHASE3	COMPLETED	Study of Mepolizumab Autoinjector in Asthmatics
NCT03298061	PHASE3	COMPLETED	Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
NCT03306043	PHASE3	COMPLETED	A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
NCT03562195	PHASE3	COMPLETED	A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
NCT04075331	PHASE2/PHASE3	COMPLETED	Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
NCT04133909	PHASE3	COMPLETED	Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).